4 - Serina Therapeutics, Inc. (0001708599) (Issuer)

4 - Serina Therapeutics, Inc. (0001708599) (Issuer)

4 - Serina Therapeutics, Inc. (0001708599) (Issuer)

4 - Serina Therapeutics, Inc. (0001708599) (Issuer)

4 - Serina Therapeutics, Inc. (0001708599) (Issuer)

4 - Serina Therapeutics, Inc. (0001708599) (Issuer)

4 - Serina Therapeutics, Inc. (0001708599) (Issuer)

4 - Serina Therapeutics, Inc. (0001708599) (Issuer)

4 - Serina Therapeutics, Inc. (0001708599) (Issuer)

4 - Serina Therapeutics, Inc. (0001708599) (Issuer)

SC 13D/A - Serina Therapeutics, Inc. (0001708599) (Subject)

SC 13G/A - Serina Therapeutics, Inc. (0001708599) (Subject)

SC 13D/A - Serina Therapeutics, Inc. (0001708599) (Subject)

4 - Serina Therapeutics, Inc. (0001708599) (Issuer)

4 - Serina Therapeutics, Inc. (0001708599) (Issuer)

4 - Serina Therapeutics, Inc. (0001708599) (Issuer)

4 - Serina Therapeutics, Inc. (0001708599) (Issuer)

3 - Serina Therapeutics, Inc. (0001708599) (Issuer)

4 - Serina Therapeutics, Inc. (0001708599) (Issuer)

4 - Serina Therapeutics, Inc. (0001708599) (Issuer)

3 - Serina Therapeutics, Inc. (0001708599) (Issuer)

4 - Serina Therapeutics, Inc. (0001708599) (Issuer)

4 - Serina Therapeutics, Inc. (0001708599) (Issuer)

- Renowned neuroscience drug developer joins to support strategic development of long-acting CNS therapeutics – HUNTSVILLE, AL, May 22, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company developing a pipeline of product candidates leveraging its proprietary POZ Platform™ drug optimization technology, today announced the appointment of Stephen (Steve) Brannan, M.D., to its Board of Directors. Dr. Brannan brings more than three decades of experience in neuroscience and neuropsychiatry drug development, with a proven track record of leading clinical programs from early development through regulatory approval and commercialization

HUNTSVILLE, AL, May 14, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company advancing its lead IND candidate SER-252 for advanced Parkinson's disease, enabled by its proprietary POZ Platform™ drug optimization technology, announced that it has made grants of options to purchase an aggregate of 15,000 shares of Serina's common stock to two new non-executive employees on March 20, 2025 (each, an "Option Grant"). Each Option Grant has an exercise price equal to the closing price of Serina's common stock on March 20, 2025. The Option Grants were offered as material inducement to the employees' employment. The Option Grants were appro

On track for first patient dosing of SER-252 in Phase 1b clinical trial in advanced Parkinson's disease in Q4 2025Strengthened balance sheet with recent financingAdvancing innovative POZ Platform across multiple therapeutic modalitiesTwo new seasoned biotech leaders added to the Board of Directors HUNTSVILLE, May 08, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today reported its financial results for the first quarter ended March 31, 2025, along with recent business highlights. "We are energized by the substantial progress and strengthened foundation

HUNTSVILLE, AL, April 29, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, announced that Steve Ledger, Chief Executive Officer, will present at the JonesResearch Hosts: Virtual CNS Day on April 29, 2025, at 12:00 p.m. EDT. A live webcast of the fireside chat style presentation will be accessible to registered attendees via the following link: https://us02web.zoom.us/webinar/register/WN_oRKPxli0QZydCUBHvEyBHQ#/registration. An archived replay will be available on-demand for 90 days following the event. About Serina Therapeutics Serina is a clinical-stage

HUNTSVILLE, AL, April 15, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, announced that Randall Moreadith, M.D., Ph.D., Chief Development Officer, will present new data at the 4th LNP Formulation & Process Development Summit 2025 in Boston, MA. The presentation, titled "The PEG Dilemma – A Solution," will take place on Tuesday, April 15, at 9:30 AM ET. The session will focus on addressing challenges related to anti-PEG antibodies in mRNA vaccines and therapeutics and introduces Serina's POZ-lipid technology as an immune-silent alternative to PEG-lipids.

HUNTSVILLE, Ala., April 08, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced the closing of a $5 million financing from strategic shareholders. Proceeds from the transaction will support the continued development of SER-252 (POZ-apomorphine), Serina's lead clinical candidate for Advanced Parkinson's disease, as the company prepares to initiate a Phase 1 clinical trial in the fourth quarter of 2025. "This financing further strengthens our cash position and reflects the confidence of our strategic investors in the potential of SER-252," said

HUNTSVILLE, AL, April 07, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, announced that Steve Ledger, Chief Executive Officer, will present at the Jones Healthcare and Technology Innovation Conference in Las Vegas, NV on April 9, 2025, at 3:00 p.m. PDT. A live webcast of the presentation will be accessible to registered attendees at this link. An archived replay will be available on-demand for 90 days following the event. About Serina Therapeutics Serina is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candid

HUNTSVILLE, March 24, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today reported its financial results for the full year ended December 31, 2024 and provided recent business highlights. "We are encouraged by the progress we've made this year. Our partnership with Enable Injections' wearable technology, combined with our POZ optimization technology, is poised to deliver a differentiated product profile and potential best-in-class therapy for advanced Parkinson's patient care. We are on track towards our goal of dosing the first patient in a Phase 1b cl

HUNTSVILLE, AL, March 24, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug delivery technology, announced that Randall Moreadith, M.D., Ph.D., Chief Development Officer, will present new data at the ACS Spring 2025 Meeting and Expo in San Diego, CA. His presentation, titled "A Non-Immunogenic LNP for Gene Delivery: Characterization of Poly(oxazoline) Lipid Nanoparticles," will highlight findings on the immunogenic profile of Serina's proprietary POZ-lipid technology. Dr. Moreadith will share data demonstrating that Serina's POZ-lipid, a key component of lipid nanoparticles (LNPs),

HUNTSVILLE, AL, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced the appointment of Jay Venkatesan, MD, MBA, to its Board of Directors. Dr. Venkatesan brings deep expertise in biotechnology investment, company building, and strategic growth, having successfully led and advised multiple biopharma companies through pivotal stages of development, including high-profile mergers and acquisitions. Dr. Venkatesan most recently served as Chairman, President, and CEO of Angion Biomedica until its merger with Elicio Therapeutics in 2023. He

8-K - Serina Therapeutics, Inc. (0001708599) (Filer)

8-K - Serina Therapeutics, Inc. (0001708599) (Filer)

10-Q - Serina Therapeutics, Inc. (0001708599) (Filer)

8-K - Serina Therapeutics, Inc. (0001708599) (Filer)

EFFECT - Serina Therapeutics, Inc. (0001708599) (Filer)

424B5 - Serina Therapeutics, Inc. (0001708599) (Filer)

S-3 - Serina Therapeutics, Inc. (0001708599) (Filer)

8-K - Serina Therapeutics, Inc. (0001708599) (Filer)

8-K - Serina Therapeutics, Inc. (0001708599) (Filer)

EFFECT - Serina Therapeutics, Inc. (0001708599) (Filer)